[1] Turkmen S, Dogdu O, Tekin K,et al. The relationship between neutrophil/lymphocyte ratio and the TIMI flow grade in patients with STEMI undergoing primary PCI[J].Eur Rev Med Pharmacol Sci,2013, 17(16): 2185-2189. [2] 杨健,罗瑛,李淑均,等.替罗非班不同给药途径对急性心肌梗死患者的临床疗效分析[J].医学临床研究,2015,32(4):718-720. [3] 范吉利,尚文涛,周元松,等.盐酸替罗非班联合替格瑞洛在急性冠脉综合征合并糖尿病患者 PCI 围术期的安全性研究[J].医学临床研究,2016,33(6):1239-1240,1241. [4] Ben-Dor I, Kleiman NS, Lev E. Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy [J].Am J Cardiol,2009, 104(2): 227-233. [5] Schneider DJ. Current issues with glycoprotein Ⅱb-Ⅲa antagonists[J].Curr Drug Targets,2011, 12(12): 1813-2180. [6] 郭华,王佟,孙笑眉,等.替罗非班冠状动脉给药对急性ST段抬高型心肌梗死患者介入治疗的临床疗效及外周血内PMPs水平的影响[J].中国药物警戒,2017,14(3):145-149. [7] 李益民, 黄进, 张晶,等. 替罗非班冠状动脉给药对ST段抬高型急性心肌梗死患者血小板微粒及短期疗效的影响[J].中华老年医学杂志, 2016, 35(5):482-486. [8] 薛丽佳,崔贝贝,李茜,等.血小板微粒及其表面标记物CD62P、CD154与类风湿关节炎的相关性研究[J].四川大学学报(医学版),2017,48(3):405-409. [9] Suades R, Padró T, Vilahur G. Circulating and platelet-derived microparticles in human blood enhance thrombosis on atherosclerotic plaques[J].Thromb Haemost,2012,108(6):1208-1219. [10] 王立中, 董鹏, 刘芳,等. 尼可地尔联合替罗非班对急性心肌梗死患者急诊PCI术后心肌微循环和心功能短期预后的影响[J].现代中西医结合杂志, 2016, 25(17):1834-1836.
2018, Vol. 35 
